目的：本研究的目的是调查基于人群的流行病学，生存结果，和恶性颈动脉体瘤（CBT）的预后因素。
方法：在1975年至2018年之间诊断为恶性CBTs的患者从9个监测登记册中进行筛查。流行病学,和结束结果(SEER)数据库。编码为“颈动脉体瘤”的病例，我们筛选了恶性\"或原发部位记录为\"颈动脉体\"的恶性肿瘤纳入研究.用SEER*Stat软件计算恶性CBT的发生率。使用Kaplan-Meier方法和对数秩检验分析生存结果。
结果：共有72例恶性CBT患者被筛选纳入研究，包括41名女性(56.9%)和31名男性(43.1%)。根据SEER程序数据，恶性CBT的发病率每年在每10万人中0至0.02例之间波动，1990年后缓慢但明显的上升。最常见的受影响人群包括35至44岁的女性和患者，分别占研究患者的59.9％和27.8％，分别。在82个月的中位随访中，四名患者失去了随访，28人死亡。其中,20人被认为是疾病特异性死亡。进一步分析发现,5年和10年总生存率分别为78.9%和67.8%,分别,而5年和10年疾病特异性生存率分别为84.5%和75.2%，分别。Kaplan-Meier方法和对数秩检验表明，年龄<50岁，性别,种族,肿瘤数量,手术治疗与总生存期和疾病特异性生存期无关.
结论：对SEER数据库的回顾性审查发现，恶性CBT的发生率极为罕见，并且容易波动，但随着时间的推移，它逐渐呈上升趋势。发现恶性CBT更有可能影响女性，它可以在任何年龄被诊断出来。恶性CBT的总体预后似乎良好，5年和10年生存率可接受。由于许多因素使恶性CBT手术复杂化，应谨慎考虑手术治疗。
OBJECTIVE: The objective of this study was to investigate population-based epidemiology, survival outcomes, and prognostic factors of malignant carotid body tumors (CBTs).
METHODS: Patients with malignant CBTs who were diagnosed between 1975 and 2018 were screened from nine registries of the Surveillance, Epidemiology, and End Results (SEER) database. Cases that were coded as \"carotid body tumor, malignant\" or malignant tumors with the primary site recorded as \"carotid body\" were screened for inclusion in the study. The incidence of malignant CBT was calculated with SEER∗Stat software. Survival outcomes were analyzed using the Kaplan-Meier method and log-rank tests.
RESULTS: A total of 72 patients with malignant CBT were screened for inclusion in the study, including 41 females (56.9%) and 31 males (43.1%). Based on the SEER program data, the incidence of malignant CBT was found to fluctuate between 0 to 0.02 cases per 100,000 people per year, with a slow but noticeable uptick after 1990. The most commonly affected populations included women and patients between the ages of 35 and 44, which accounted for 59.9% and 27.8% of patients in the study, respectively. During a median follow-up of 82 months, four patients were lost to follow-up, and 28 deaths were identified. Of those, 20 were considered disease-specific deaths. Further analysis found that the 5-year and 10-year overall survival rates were 78.9% and 67.8%, respectively, whereas the 5-year and 10-year disease-specific survival rates were 84.5% and 75.2%, respectively. The Kaplan-Meier method and log-rank tests indicated that age <50 years, sex, race, tumor number, and surgical treatment were unrelated to both overall survival and disease-specific survival.
CONCLUSIONS: A retrospective review of the SEER database found that the incidence of malignant CBT was extremely rare and prone to fluctuation, but that it slowly trended upward over time. Malignant CBT was found to more likely affect females, and it could be diagnosed at any age. The overall prognosis for malignant CBT appeared to be good, with acceptable 5-year and 10-year survival rates. Due to a number of factors complicating malignant CBT surgery, surgical treatment should be considered with caution.
PDF(Pubmed)